Center for Neuropsychiatric Schizophrenia Research and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, København, Denmark.
Psychol Med. 2020 Jan;50(2):220-228. doi: 10.1017/S0033291718004099. Epub 2019 Jan 15.
Psychotic symptoms have been linked to salience abnormalities in the brain reward system, perhaps caused by a dysfunction of the dopamine neurotransmission in striatal regions. Blocking dopamine D2 receptors dampens psychotic symptoms and normalises reward disturbances, but a direct relationship between D2 receptor blockade, normalisation of reward processing and symptom improvement has not yet been demonstrated. The current study examined the association between blockade of D2 receptors in the caudate nucleus, alterations in reward processing and the psychopathology in a longitudinal study of antipsychotic-naïve first-episode schizophrenia patients.
Twenty-two antipsychotic-naïve first-episode schizophrenia patients (10 males, mean age 23.3) and 23 healthy controls (12 males, mean age 23.5) were examined with single-photon emission computed tomography using 123I-labelled iodobenzamide. Reward disturbances were measured with functional magnetic resonance imaging (fMRI) using a modified version of the monetary-incentive-delay task. Patients were assessed before and after 6 weeks of treatment with amisulpride.
In line with previous results, patients had a lower fMRI response at baseline (0.2 ± 0.5 v. 0.7 ± 0.6; p = 0.008), but not at follow-up (0.5 ± 0.6 v. 0.6 ± 0.7), and a change in the fMRI signal correlated with improvement in Positive and Negative Syndrome Scale positive symptoms (ρ = -0.435, p = 0.049). In patients responding to treatment, a correlation between improvement in the fMRI signal and receptor occupancy was found (ρ = 0.588; p = 0.035).
The results indicate that salience abnormalities play a role in the reward system in schizophrenia. In patients responding to a treatment-induced blockade of dopamine D2 receptors, the psychotic symptoms may be ameliorated by normalising salience abnormalities in the reward system.
精神症状与大脑奖励系统中的突显异常有关,这可能是由于纹状体区域的多巴胺神经传递功能障碍引起的。阻断多巴胺 D2 受体可减轻精神病症状并使奖励处理正常化,但 D2 受体阻断、奖励处理正常化与症状改善之间的直接关系尚未得到证明。本研究在一项抗精神病药物初发的首发精神分裂症患者的纵向研究中,检测了尾状核 D2 受体阻断与奖励处理改变与精神病理学之间的关系。
22 例抗精神病药物初发的首发精神分裂症患者(男 10 例,平均年龄 23.3 岁)和 23 名健康对照者(男 12 例,平均年龄 23.5 岁)接受了 123I-碘苯甲酰胺标记的单光子发射计算机断层扫描检查。使用修改后的货币奖励延迟任务,通过功能磁共振成像(fMRI)测量奖励障碍。患者在服用氨磺必利治疗 6 周前后接受评估。
与之前的结果一致,患者在基线时的 fMRI 反应较低(0.2 ± 0.5 比 0.7 ± 0.6;p = 0.008),但在随访时无差异(0.5 ± 0.6 比 0.6 ± 0.7),并且 fMRI 信号的变化与阳性和阴性综合征量表阳性症状的改善相关(ρ=-0.435,p=0.049)。在对治疗有反应的患者中,发现 fMRI 信号改善与受体占有率之间存在相关性(ρ=0.588;p=0.035)。
研究结果表明,突显异常在精神分裂症的奖励系统中起作用。在对治疗诱导的多巴胺 D2 受体阻断有反应的患者中,通过使奖励系统中的突显异常正常化,精神病症状可能得到改善。